Average Co-Inventor Count = 11.45
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Novartis Ag (16 from 3,923 patents)
2. University of Pennsylvania (5 from 2,597 patents)
3. Dana-farber-cancer Institute Inc. (5 from 1,209 patents)
4. Children's Medical Center Corporation (5 from 1,036 patents)
5. Unversität Zürich (2 from 164 patents)
18 patents:
1. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
2. 11851484 - Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
3. 11155620 - Method of detecting TIM-3 using antibody molecules to TIM-3
4. 11149076 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
5. 11111293 - IL-18 binding molecules
6. 11026976 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
7. 10981990 - Antibody molecules to TIM-3 and uses thereof
8. 10889643 - Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
9. 10865237 - Nucleic acids encoding anti-Factor P antibodies
10. 10525083 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
11. 10472419 - Antibody molecules to TIM-3 and uses thereof
12. 10253086 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
13. 10081677 - IL-18 binding molecules
14. 9988440 - Compositions comprising antibodies targeting factor P
15. 9884913 - Antibody molecules to TIM-3 and uses thereof